Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Journal of the National Comprehensive Cancer Network : JNCCN|September 4, 2020
A Practical Guide for Using Myelofibrosis Prognostic Models in the ClinicJoan How, Gabriela S Hobbs
Current Opinion in Hematology|January 31, 2015
Clinical and molecular genetic characterization of myelofibrosisGabriela S Hobbs, Raajit K Rampal
Hematology/Oncology Clinics of North America|July 5, 2017
The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative NeoplasmsGabriela S Hobbs, Sarah Rozelle, Ann Mullally
Blood|September 29, 2019
Mutant calreticulin in myeloproliferative neoplasmsJoan How, Gabriela S Hobbs, Ann Mullally
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|May 2, 2022
Incidence of bleeding events in patients on concomitant tyrosine kinase inhibitors and selective serotonin reuptake inhibitorsVinayak Venkataraman, John R Bales, Jessie Signorelli, et al.
Blood Cancer Journal|November 6, 2021
Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patientsJoan How, Charlotte Story, Siyang Ren, et al.
Blood Advances|October 7, 2025
Myeloproliferative neoplasm subtypes have distinct impact on risk of incident osteoporosis and osteoporotic fracturesMichelle H Lee, Yating Wang, Angel M Cronin, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 13, 2024
Dose Modifications in the Management of Chronic Phase Chronic Myeloid Leukemia: Who, What, and WhenVivian G Oehler, Ivan J Huang, Chloe Siu, et al.
Pageof 5